
天津医药 ›› 2026, Vol. 54 ›› Issue (11): 1136-1143.doi: 10.11958/20261603
收稿日期:2026-06-17
修回日期:2026-08-14
出版日期:2026-11-15
发布日期:2026-11-10
作者简介:杨龙(1987),男,主治医师,主要从事普通外科的基础与临床方面研究。E-mail:yanglong2563@163.com
基金资助:
YANG Long(
), ZHAO Jiangqiao, DONG Zhiqiang
Received:2026-06-17
Revised:2026-08-14
Published:2026-11-15
Online:2026-11-10
杨龙, 赵江桥, 董志强. LncRNA SNHG25调节miR-6838-5p/ISOC1轴对胃癌细胞生物学行为的影响[J]. 天津医药, 2026, 54(11): 1136-1143.
YANG Long, ZHAO Jiangqiao, DONG Zhiqiang. Effects of LncRNA SNHG25 on the proliferation, migration and epithelial-mesenchymal transition of gastric cancer cells by regulating the miR-6838-5p/ISOC1 axis[J]. Tianjin Medical Journal, 2026, 54(11): 1136-1143.
摘要:
目的 探究长链非编码RNA(LncRNA)小核仁RNA宿主基因(SNHG)25调节微小RNA(miR)-6838-5p/含异分支酶结构域1(ISOC1)轴对胃癌(GC)细胞生物学行为的影响。方法 体外培养GES-1、HGC-27、AGS、MGC-803细胞,通过实时荧光定量逆转录聚合酶链式反应(qRT-PCR)及Western blot法检测LncRNA SNHG25、miR-6838-5p及ISOC1表达,筛选差异最显著的细胞系用于后续实验。将筛选出的HGC-27细胞分为Con组、si-NC组、si-SNHG25组、si-SNHG25+NC组、si-SNHG25+miR-6838-5p inhibitor组、si-SNHG25+pcDNA-NC组、si-SNHG25+ISOC1组。 5-乙炔基-2ʹ-脱氧尿嘧啶核苷(EdU)染色、流式细胞术、划痕实验、Western blot检测各组细胞增殖、凋亡、迁移及相关蛋白表达;双萤光素酶报告实验和RNA免疫沉淀(RIP)实验分析LncRNA SNHG25、miR-6838-5p、ISOC1间靶向关系。结果 HGC-27、AGS、MGC-803细胞较GES-1细胞LncRNA SNHG25、ISOC1 mRNA和蛋白表达增加,miR-6838-5p减少(P<0.05),HGC-27变化最显著,选HGC-27为后续实验细胞。si-SNHG25组较Con组、si-NC组细胞EdU阳性率、划痕愈合率、LncRNA SNHG25、ISOC1 mRNA及蛋白、Ki-67蛋白(Ki-67)、细胞周期蛋白D1(Cyclin D1)、波形蛋白(Vimentin)、纤连蛋白(FN)减少,凋亡率、miR-6838-5p、Bcl-2相关X蛋白(Bax)、裂解的胱天蛋白酶-3(cleaved caspase-3)、E-钙黏蛋白(E-cadherin)增加(P<0.05);共转染miR-6838-5p inhibitor或ISOC1均可逆转上述变化。双萤光素酶和RIP证实三者存在靶向结合。结论 沉默LncRNA SNHG25可能通过海绵吸附miR-6838-5p下调ISOC1,抑制GC细胞增殖、迁移及上皮间质转化,并促进细胞凋亡。
中图分类号:
| 基因 | 引物序列(5ʹ→3ʹ) | 产物大小/bp |
|---|---|---|
| LncRNA SNHG25 | 上游:GCAGGTTCCGGGAGGTCA | 89 |
| 下游:CAAACCACTTTATTGACGGGAA | ||
| miR-6838-5p | 上游:GTATGAGAAGCAGCAGTGGCAA | 69 |
| 下游:CTCAACTGGTGTCGTGGAG | ||
| ISOC1 | 上游:AGCGTTAGCCGAGATTCCTG | 112 |
| 下游:CCAGGGCAGTTTGCTGGATA | ||
| GAPDH | 上游:GGGCCAAAAGGGTCATCATC | 140 |
| 下游:ATGACCTTGCCCACAGCCTT | ||
| U6 | 上游:CGCTTCGGCAGCACATATAC | 94 |
| 下游:TTCACGAATTTGCGTGTCAT |
表1 qRT-PCR引物序列
Tab.1 qRT-PCR primer sequences
| 基因 | 引物序列(5ʹ→3ʹ) | 产物大小/bp |
|---|---|---|
| LncRNA SNHG25 | 上游:GCAGGTTCCGGGAGGTCA | 89 |
| 下游:CAAACCACTTTATTGACGGGAA | ||
| miR-6838-5p | 上游:GTATGAGAAGCAGCAGTGGCAA | 69 |
| 下游:CTCAACTGGTGTCGTGGAG | ||
| ISOC1 | 上游:AGCGTTAGCCGAGATTCCTG | 112 |
| 下游:CCAGGGCAGTTTGCTGGATA | ||
| GAPDH | 上游:GGGCCAAAAGGGTCATCATC | 140 |
| 下游:ATGACCTTGCCCACAGCCTT | ||
| U6 | 上游:CGCTTCGGCAGCACATATAC | 94 |
| 下游:TTCACGAATTTGCGTGTCAT |
| 细胞系 | LncRNA SNHG25 | miR-6838-5p | ISOC1 mRNA | ISOC1 蛋白 |
|---|---|---|---|---|
| GES-1 | 1.01±0.08 | 0.99±0.09 | 1.03±0.12 | 0.34±0.05 |
| AGS | 1.76±0.19a | 0.51±0.08a | 2.01±0.21a | 0.65±0.09a |
| MGC-803 | 1.68±0.16a | 0.48±0.06a | 1.83±0.19a | 0.58±0.07a |
| HGC-27 | 2.09±0.21abc | 0.32±0.05abc | 2.36±0.24abc | 1.09±0.11abc |
| F | 43.872** | 97.282** | 50.001** | 85.130** |
表2 各细胞系LncRNA SNHG25、miR-6838-5p、ISOC1 mRNA及ISOC1蛋白表达比较(n=6,$\bar{x}±s$)
Tab.2 Comparison of LncRNA SNHG25, miR-6838-5p and ISOC1 mRNA and protein expression between different cell lines
| 细胞系 | LncRNA SNHG25 | miR-6838-5p | ISOC1 mRNA | ISOC1 蛋白 |
|---|---|---|---|---|
| GES-1 | 1.01±0.08 | 0.99±0.09 | 1.03±0.12 | 0.34±0.05 |
| AGS | 1.76±0.19a | 0.51±0.08a | 2.01±0.21a | 0.65±0.09a |
| MGC-803 | 1.68±0.16a | 0.48±0.06a | 1.83±0.19a | 0.58±0.07a |
| HGC-27 | 2.09±0.21abc | 0.32±0.05abc | 2.36±0.24abc | 1.09±0.11abc |
| F | 43.872** | 97.282** | 50.001** | 85.130** |
图2 各组细胞EdU染色结果(×200) A:Con组;B:si-NC组;C:si-SNHG25组;D:si-SNHG25+NC组;E:si-SNHG25+miR-6838-5p inhibitor组;F:si-SNHG25+pcDNA-NC组;G:si-SNHG25+ISOC1组。图3—8同。
Fig.2 EdU staining of cells in each group (×200)
| 组别 | EdU阳性率/% | Ki-67 | Cyclin D1 |
|---|---|---|---|
| Con组 | 45.39±6.02 | 1.02±0.13 | 1.01±0.12 |
| si-NC组 | 43.75±5.26 | 1.01±0.15 | 0.99±0.13 |
| si-SNHG25组 | 16.93±1.95ab | 0.46±0.07ab | 0.41±0.04ab |
| si-SNHG25+NC组 | 16.57±1.83 | 0.43±0.05 | 0.39±0.05 |
| si-SNHG25+miR-6838-5p inhibitor组 | 34.82±3.64cd | 0.85±0.09cd | 0.76±0.08cd |
| si-SNHG25+pcDNA-NC组 | 16.73±1.72 | 0.45±0.06 | 0.42±0.05 |
| si-SNHG25+ISOC1组 | 35.49±3.86ce | 0.82±0.08ce | 0.75±0.09ce |
| F | 68.964** | 45.904** | 58.882** |
表3 各组细胞EdU阳性率、Ki-67、Cyclin D1表达比较(n=6,$\bar{x}±s$)
Tab.3 Comparison of EdU-positive rate and expression of Ki-67 and Cyclin D1 between seven groups of cells
| 组别 | EdU阳性率/% | Ki-67 | Cyclin D1 |
|---|---|---|---|
| Con组 | 45.39±6.02 | 1.02±0.13 | 1.01±0.12 |
| si-NC组 | 43.75±5.26 | 1.01±0.15 | 0.99±0.13 |
| si-SNHG25组 | 16.93±1.95ab | 0.46±0.07ab | 0.41±0.04ab |
| si-SNHG25+NC组 | 16.57±1.83 | 0.43±0.05 | 0.39±0.05 |
| si-SNHG25+miR-6838-5p inhibitor组 | 34.82±3.64cd | 0.85±0.09cd | 0.76±0.08cd |
| si-SNHG25+pcDNA-NC组 | 16.73±1.72 | 0.45±0.06 | 0.42±0.05 |
| si-SNHG25+ISOC1组 | 35.49±3.86ce | 0.82±0.08ce | 0.75±0.09ce |
| F | 68.964** | 45.904** | 58.882** |
| 组别 | 凋亡率/% | Bax | cleaved caspase-3 |
|---|---|---|---|
| Con组 | 1.85±0.24 | 0.42±0.06 | 0.39±0.05 |
| si-NC组 | 1.96±0.21 | 0.39±0.04 | 0.41±0.06 |
| si-SNHG25组 | 42.57±5.63ab | 0.98±0.12ab | 0.99±0.14ab |
| si-SNHG25+NC组 | 41.28±4.57 | 0.96±0.09 | 0.96±0.12 |
| si-SNHG25+miR-6838-5p inhibitor组 | 9.24±1.05cd | 0.51±0.06cd | 0.45±0.05cd |
| si-SNHG25+pcDNA-NC组 | 39.63±5.85 | 0.96±0.09 | 0.98±0.11 |
| si-SNHG25+ISOC1组 | 11.49±1.72ce | 0.49±0.05ce | 0.50±0.06ce |
| F | 167.865** | 77.375** | 60.741** |
表4 各组细胞凋亡率、Bax、cleaved caspase-3表达比较(n=6,$\bar{x}±s$)
Tab.4 Comparison of apoptosis rate and expression of Bax and cleaved caspase-3 between seven groups of cells
| 组别 | 凋亡率/% | Bax | cleaved caspase-3 |
|---|---|---|---|
| Con组 | 1.85±0.24 | 0.42±0.06 | 0.39±0.05 |
| si-NC组 | 1.96±0.21 | 0.39±0.04 | 0.41±0.06 |
| si-SNHG25组 | 42.57±5.63ab | 0.98±0.12ab | 0.99±0.14ab |
| si-SNHG25+NC组 | 41.28±4.57 | 0.96±0.09 | 0.96±0.12 |
| si-SNHG25+miR-6838-5p inhibitor组 | 9.24±1.05cd | 0.51±0.06cd | 0.45±0.05cd |
| si-SNHG25+pcDNA-NC组 | 39.63±5.85 | 0.96±0.09 | 0.98±0.11 |
| si-SNHG25+ISOC1组 | 11.49±1.72ce | 0.49±0.05ce | 0.50±0.06ce |
| F | 167.865** | 77.375** | 60.741** |
图7 Western blot检测各组细胞E-cadherin、Vimentin、FN蛋白表达
Fig.7 Expression levels of E-cadherin, Vimentin and FN proteins detected by Western blot assay in each group of cells
| 组别 | 划痕愈合率/% | Vimentin |
|---|---|---|
| Con组 | 72.67±9.83 | 1.02±0.09 |
| si-NC组 | 71.92±8.05 | 1.01±0.13 |
| si-SNHG25组 | 33.41±3.54ab | 0.39±0.06ab |
| si-SNHG25+NC组 | 32.75±4.36 | 0.41±0.05 |
| si-SNHG25+miR-6838-5p nhibitor组 | 59.62±7.12cd | 0.83±0.08cd |
| si-SNHG25+pcDNA-NC组 | 32.94±4.51 | 0.38±0.04 |
| si-SNHG25+ISOC1组 | 57.71±6.76ce | 0.81±0.08ce |
| F | 45.044** | 78.422** |
| 组别 | FN | E-cadherin |
| Con组 | 0.99±0.08 | 0.35±0.04 |
| si-NC组 | 1.02±0.09 | 0.37±0.06 |
| si-SNHG25组 | 0.51±0.05ab | 0.95±0.11ab |
| si-SNHG25+NC组 | 0.49±0.03 | 0.93±0.15 |
| si-SNHG25+miR-6838-5p nhibitor组 | 0.91±0.09cd | 0.42±0.06cd |
| si-SNHG25+pcDNA-NC组 | 0.48±0.05 | 0.91±0.09 |
| si-SNHG25+ISOC1组 | 0.87±0.09ce | 0.45±0.05ce |
| F | 70.486** | 63.930** |
表5 各组细胞划痕愈合率、Vimentin、FN、E-cadherin表达比较(n=6,$\bar{x}±s$)
Tab.5 Comparison of wound healing rate and expression of Vimentin, FN and E-cadherin between seven groups of cells
| 组别 | 划痕愈合率/% | Vimentin |
|---|---|---|
| Con组 | 72.67±9.83 | 1.02±0.09 |
| si-NC组 | 71.92±8.05 | 1.01±0.13 |
| si-SNHG25组 | 33.41±3.54ab | 0.39±0.06ab |
| si-SNHG25+NC组 | 32.75±4.36 | 0.41±0.05 |
| si-SNHG25+miR-6838-5p nhibitor组 | 59.62±7.12cd | 0.83±0.08cd |
| si-SNHG25+pcDNA-NC组 | 32.94±4.51 | 0.38±0.04 |
| si-SNHG25+ISOC1组 | 57.71±6.76ce | 0.81±0.08ce |
| F | 45.044** | 78.422** |
| 组别 | FN | E-cadherin |
| Con组 | 0.99±0.08 | 0.35±0.04 |
| si-NC组 | 1.02±0.09 | 0.37±0.06 |
| si-SNHG25组 | 0.51±0.05ab | 0.95±0.11ab |
| si-SNHG25+NC组 | 0.49±0.03 | 0.93±0.15 |
| si-SNHG25+miR-6838-5p nhibitor组 | 0.91±0.09cd | 0.42±0.06cd |
| si-SNHG25+pcDNA-NC组 | 0.48±0.05 | 0.91±0.09 |
| si-SNHG25+ISOC1组 | 0.87±0.09ce | 0.45±0.05ce |
| F | 70.486** | 63.930** |
| 组别 | LncRNA SNHG25 | miR-6838-5p |
|---|---|---|
| Con组 | 1.03±0.11 | 0.98±0.08 |
| si-NC组 | 1.01±0.09 | 0.99±0.12 |
| si-SNHG25组 | 0.32±0.03ab | 2.01±0.25ab |
| si-SNHG25+NC组 | 0.31±0.04 | 1.98±0.21 |
| si-SNHG25+miR-6838-5p nhibitor组 | 0.34±0.03 | 1.18±0.13cd |
| si-SNHG25+pcDNA-NC组 | 0.32±0.04 | 2.03±0.22 |
| si-SNHG25+ISOC1组 | 0.33±0.05 | 2.04±0.21 |
| F | 175.061** | 48.003** |
| 组别 | ISOC1 mRNA | ISOC1 蛋白 |
| Con组 | 1.03±0.12 | 0.99±0.08 |
| si-NC组 | 1.02±0.15 | 1.03±0.13 |
| si-SNHG25组 | 0.43±0.06ab | 0.39±0.04ab |
| si-SNHG25+NC组 | 0.45±0.05 | 0.37±0.05 |
| si-SNHG25+miR-6838-5p nhibitor组 | 0.81±0.08cd | 0.78±0.09cd |
| si-SNHG25+pcDNA-NC组 | 0.42±0.07 | 0.41±0.05 |
| si-SNHG25+ISOC1组 | 0.86±0.11ce | 0.75±0.07ce |
| F | 48.572** | 79.361** |
表6 各组细胞LncRNA SNHG25、miR-6838-5p以及ISOC1表达比较(n=6,$\bar{x}±s$)
Tab.6 Comparison of LncRNA SNHG25, miR-6838-5p and ISOC1 expression between seven groups of cells
| 组别 | LncRNA SNHG25 | miR-6838-5p |
|---|---|---|
| Con组 | 1.03±0.11 | 0.98±0.08 |
| si-NC组 | 1.01±0.09 | 0.99±0.12 |
| si-SNHG25组 | 0.32±0.03ab | 2.01±0.25ab |
| si-SNHG25+NC组 | 0.31±0.04 | 1.98±0.21 |
| si-SNHG25+miR-6838-5p nhibitor组 | 0.34±0.03 | 1.18±0.13cd |
| si-SNHG25+pcDNA-NC组 | 0.32±0.04 | 2.03±0.22 |
| si-SNHG25+ISOC1组 | 0.33±0.05 | 2.04±0.21 |
| F | 175.061** | 48.003** |
| 组别 | ISOC1 mRNA | ISOC1 蛋白 |
| Con组 | 1.03±0.12 | 0.99±0.08 |
| si-NC组 | 1.02±0.15 | 1.03±0.13 |
| si-SNHG25组 | 0.43±0.06ab | 0.39±0.04ab |
| si-SNHG25+NC组 | 0.45±0.05 | 0.37±0.05 |
| si-SNHG25+miR-6838-5p nhibitor组 | 0.81±0.08cd | 0.78±0.09cd |
| si-SNHG25+pcDNA-NC组 | 0.42±0.07 | 0.41±0.05 |
| si-SNHG25+ISOC1组 | 0.86±0.11ce | 0.75±0.07ce |
| F | 48.572** | 79.361** |
| 组别 | SNHG25-WT | SNHG25-MUT | ISOC1-WT | ISOC1-MUT |
|---|---|---|---|---|
| 对照组 | 1.00±0.05 | 1.02±0.03 | 0.99±0.06 | 1.01±0.05 |
| 实验组 | 0.37±0.06 | 0.99±0.05 | 0.41±0.08 | 0.98±0.04 |
| t | 19.687** | 1.239 | 14.240** | 1.162 |
表7 miR-6838-5p过表达对SNHG25和ISOC1 WT及MUT质粒活性的影响(n=6,$\bar{x}±s$)
Tab.7 Effects of miR-6838-5p overexpression on the dual-luciferase activities of wild-type and mutant reporter plasmids containing SNHG25 and ISOC1
| 组别 | SNHG25-WT | SNHG25-MUT | ISOC1-WT | ISOC1-MUT |
|---|---|---|---|---|
| 对照组 | 1.00±0.05 | 1.02±0.03 | 0.99±0.06 | 1.01±0.05 |
| 实验组 | 0.37±0.06 | 0.99±0.05 | 0.41±0.08 | 0.98±0.04 |
| t | 19.687** | 1.239 | 14.240** | 1.162 |
| 抗体 | miR-6838-5p与LncRNA SNHG25 | |
|---|---|---|
| miR-6838-5p | LncRNA SNHG25 | |
| IgG | 0.99±0.06 | 1.01±0.02 |
| Ago2 | 4.75±0.51 | 6.37±0.68 |
| t | 18.007** | 19.240** |
| 抗体 | miR-6838-5p与ISOC1 mRNA | |
| miR-6838-5p | ISOC1 mRNA | |
| IgG | 1.05±0.08 | 1.02±0.11 |
| Ago2 | 5.92±0.63 | 6.05±0.61 |
| t | 18.783** | 19.854** |
表8 Ago2验证miR-6838-5p与LncRNA SNHG25、ISOC1之间的靶向关系(n=6,$\bar{x}±s$)
Tab.8 Ago2 validates the relationships between miR- 6838-5p and the LncRNA SNHG25 and ISOC1
| 抗体 | miR-6838-5p与LncRNA SNHG25 | |
|---|---|---|
| miR-6838-5p | LncRNA SNHG25 | |
| IgG | 0.99±0.06 | 1.01±0.02 |
| Ago2 | 4.75±0.51 | 6.37±0.68 |
| t | 18.007** | 19.240** |
| 抗体 | miR-6838-5p与ISOC1 mRNA | |
| miR-6838-5p | ISOC1 mRNA | |
| IgG | 1.05±0.08 | 1.02±0.11 |
| Ago2 | 5.92±0.63 | 6.05±0.61 |
| t | 18.783** | 19.854** |
| [1] | Tang L, Zhang W, Qi T, et al. Exosomes play a crucial role in remodeling the tumor microenvironment and in the treatment of gastric cancer[J]. Cell Commun Signal, 2025, 23(1):82. doi:10.1186/s12964-024-02009-7. |
| [2] | Callegarin M, Angerilli V, Gasparello J, et al. An evaluation of known predictive biomarkers for gastric cancer[J]. Expert Rev Mol Diagn, 2025, 25(11):753-773. doi:10.1080/14737159.2025.2573461. |
| [3] | Zhou F, Xie Y, Li X, et al. Juglone targets MMP-1 to inhibit gastric cancer progression[J]. Biochem Pharmacol, 2025, 242(Pt 2):117289. doi:10.1016/j.bcp.2025.117289. |
| [4] | Liu P, Li N, Guo J, et al. Immune checkpoint inhibitor therapy for gastric cancer:current status,therapeutic challenges,and future prospects[J]. Front Immunol, 2026, 17:1716934. doi:10.3389/fimmu.2026.1716934. |
| [5] | Wang L, Zhou P, Qu H, et al. Emerging role of circular RNAs in gastric cancer:From basic biology to clinical applications(Review)[J]. Mol Med Rep, 2025, 32(3):252-265. doi:10.3892/mmr.2025.13617. |
| [6] | Shin D. Perioperative nutritional treatment for patients with gastric cancer:Focusing on recent controversial issues[J]. J Gastric Cancer, 2026, 26(1):92-105. doi:10.5230/jgc.2026.26.e1. |
| [7] | Li H, Jiang H, Huang Z, et al. Construction and validation of cuproptosis-related lncRNA prediction signature for bladder cancer and immune infiltration analysis[J]. Aging(Albany NY), 2023, 15(16):8325-8344. doi:10.18632/aging.204972. |
| [8] | 曾欢, 谢程, 李红梅. LncRNA SNHG25调控miR-195-5p/HMGA1轴对宫颈癌细胞增殖、凋亡和免疫逃逸的影响[J]. 中国细胞生物学学报, 2025, 47(11):2918-2930. |
| Zeng H, Xie C, Li H M. Impacts of LncRNA SNHG25 on the proliferation,apoptosis,and immune escape of cervical cancer cells by adjusting miR-195-5p/HMGA1 axis[J]. Chinese Journal of Cell Biology, 2025, 47(11):2918-2930. doi:10.11844/cjcb.2025.11.0018. | |
| [9] | Ren S, Lee W, Park B, et al. Constructing lncRNA-miRNA-mRNA networks specific to individual cancer patients and finding prognostic biomarkers[J]. BMC Genom Data, 2024, 25(Suppl 1):67. doi:10.1186/s12863-024-01251-9. |
| [10] | Zhou W, Ding X, Jin P, et al. miR-6838-5p affects cell growth, migration, and invasion by targeting GPRIN3 via the Wnt/β-catenin signaling pathway in gastric cancer[J]. Pathobiology, 2020, 87(6):327-337. doi:10.1159/000511691. |
| [11] | Zhao J Q, Li X N, Fu L P, et al. ISOC1 promotes the proliferation of gastric cancer cells by positively regulating CDK19[J]. Eur Rev Med Pharmacol Sci, 2020, 24(22):11602-11609. doi:10.26355/eurrev_202011_23803. |
| [12] | Chen Y, Jia K, Xie Y, et al. The current landscape of gastric cancer and gastroesophageal junction cancer diagnosis and treatment in China:a comprehensive nationwide cohort analysis[J]. J Hematol Oncol, 2025, 18(1):42. doi:10.1186/s13045-025-01698-y. |
| [13] | Nagaraju G P, Kumari S, Srilatha M, et al. Cytokine epigenetics network for gastric cancer progression and chemoresistance[J]. Pharmacol Res, 2026, 225:108136. doi:10.1016/j.phrs.2026.108136. |
| [14] | Sheykhhasan M, Dermani F, Gheibi N, et al. The emerging role of LncRNA AWPPH in multiple cancers:A review study[J]. Curr Mol Med, 2025, 25(3):237-268. doi:10.2174/1566524023666230816163031. |
| [15] | Li Y, Liu W, Liu C, et al. LncRNA SNHG25 facilitates colorectal cancer progression by upregulating PPP2R2D expression through sponging miR-329-3p[J]. Cytotechnology, 2025, 77(3):89. doi:10.1007/s10616-025-00753-3. |
| [16] | Wan N, Liu Q, Shi J, et al. LncRNA SNHG25 predicts poor prognosis and promotes progression in osteosarcoma via the miR-497-5p/SOX4 axis[J]. Comb Chem High Throughput Screen, 2024, 27(5):725-744. doi:10.2174/1386207326666230602122618. |
| [17] | Zhang Y, Bi L, Li Q, et al. Design of an in vitro model for epithelial-to-mesenchymal transition in gastric cancer[J]. Biochem Genet, 2025, 63(1):698-712. doi:10.1007/s10528-024-10668-x. |
| [18] | Xu X, Wang S, Wang H, et al. Hsa_circ_0008434 regulates USP9X expression by sponging miR-6838-5p to promote gastric cancer growth, migration and invasion[J]. BMC Cancer, 2021, 21(1):1289. doi:10.1186/s12885-021-09052-4. |
| [19] | 薛良军, 谈秋瑜, 许静文, 等. MiR-6838-5p过表达下调DDR1基因表达抑制乳腺癌MCF-7细胞的增殖[J]. 南方医科大学学报, 2024, 44(9):1677-1684. |
| Xue L J, Tan Q Y, Xu J W, et al. MiR-6838-5p overexpression inhibits proliferation of breast cancer MCF-7 cells by downregulating DDR1 expression[J]. J South Med Univ, 2024, 44(9):1677-1684. doi:10.12122/j.issn.1673-4254.2024.09.07. | |
| [20] | 赵江桥, 付立平, 杨龙, 等. 敲低ISOC1抑制胃癌细胞上皮-间质转化、迁移与侵袭[J]. 现代肿瘤医学, 2025, 33(12):2070-2077. |
| Zhao J Q, Fu L P, Yang L, et al. ISOC1 knockdown suppresses epithelial-mesenchymal transition,migration,and invasion in gastric cancer cells[J]. Modern Oncology, 2025, 33(12):2070-2077. doi:10.3969/j.issn.1672-4992.2025.12.005. | |
| [21] | Shi J, Yang F, Zhou N, et al. Isochorismatase domain-containing protein 1(ISOC1)participates in DNA damage repair and inflammation-related pathways to promote lung cancer development[J]. Transl Lung Cancer Res, 2021, 10(3):1444-1456. doi:10.21037/tlcr-21-219. |
| [1] | 周颖, 董文静, 孙迪, 宋凌云, 薛哲, 庞萍, 杨国庆. 转录组与蛋白质组联合分析筛选肾上腺醛固酮瘤的核心致病基因及其生物学功能研究[J]. 天津医药, 2026, 54(9): 897-901. |
| [2] | 张佳明, 班志超, 常黎明, 周医斋. 基于NFE2L1、TRIM26表达构建并验证预测免疫治疗转移性胃癌患者生存期的列线图模型[J]. 天津医药, 2026, 54(9): 934-940. |
| [3] | 马月湘, 冯展旺, 王千雨, 彭锦雯, 王文颖, 朱镇华, 宾骥. 瑞香素调控Src/FAK通路对鼻咽癌细胞增殖、迁移和上皮间质转化的影响[J]. 天津医药, 2026, 54(8): 790-795. |
| [4] | 梁东阁, 曹欢, 张婷, 何倩倩, 黄晗, 仝瑞防. 地榆皂苷Ⅰ调节RhoA/ROCK信号通路对支原体肺炎幼鼠肺组织炎性损伤的影响[J]. 天津医药, 2026, 54(8): 808-814. |
| [5] | 张渤, 徐伟, 张静, 马肖. GFPT1通过调节PD-L1通路对非小细胞肺癌细胞的影响[J]. 天津医药, 2026, 54(7): 687-692. |
| [6] | 董倩, 陈淑华, 张飞. ACE2在结直肠癌耐药中的作用及其预测价值的研究[J]. 天津医药, 2026, 54(6): 561-569. |
| [7] | 张婧, 张明, 卫玮, 宁海虹, 韦红梅, 李海燕, 吴宾. miR-194-5p抑制剂对2型糖尿病心肌病小鼠心肌损伤的保护作用及机制探讨[J]. 天津医药, 2026, 54(6): 577-584. |
| [8] | 刘瑢, 项艳曾, 马丽娟, 张鹏. 腺病毒介导的SPRY1过表达对肝细胞癌凋亡和自噬的影响[J]. 天津医药, 2026, 54(4): 337-343. |
| [9] | 宋金萍, 崔彦杰, 王昌敏. miR-493-3p通过lncRNA CCAT2/TCF7L2轴对高糖诱导的心肌细胞损伤和凋亡的影响[J]. 天津医药, 2026, 54(4): 344-351. |
| [10] | 钱永, 陈沐秀, 郑爽. COX-2在口腔鳞状细胞癌增殖与侵袭中的作用研究[J]. 天津医药, 2026, 54(4): 352-357. |
| [11] | 刘家妮, 苏帅, 张爱婷, 徐昕, 王邦茂. 霍乱毒素抗肿瘤作用的研究进展[J]. 天津医药, 2026, 54(4): 438-443. |
| [12] | 杨晓芳, 贾新燕, 丰文君. miR-181a-5p通过HMGB1/NF-κB信号通路调控狼疮性肾炎小鼠肾小球系膜细胞增殖和凋亡[J]. 天津医药, 2026, 54(3): 232-237. |
| [13] | 张婧, 魏玉英, 宁海虹, 韦红梅, 王嘉玮, 曹薇, 吴宾. DUSP9在2型糖尿病心肌病小鼠心肌损伤中的保护作用及其机制[J]. 天津医药, 2026, 54(3): 238-244. |
| [14] | 赵丽, 马秀丽, 刘毅, 朱毅. 全麻下腹腔镜胃癌根治术后谵妄发生的危险因素分析[J]. 天津医药, 2026, 54(3): 259-264. |
| [15] | 王喆, 邱林, 马贲. 番茄来源胞外囊泡样颗粒对口腔鳞状细胞癌的作用效果研究[J]. 天津医药, 2026, 54(2): 145-150. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||